Sign in to view content

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial

Eric W Schneider, MD

Video
Published 2023

Related

Clinical Trial Versus Real-World Outcomes With Anti-VEGF Therapy for Branch and Central Retinal Vein Occlusion
Carl J Danzig, MD
Annual Meeting Talks
2021
Six Monthly Intravitreal Aflibercept to Improve Macular Perfusion in Diabetic Retinopathy Without Macular Edema
Yoon Jeon Kim, MD
Annual Meeting Talks
2023
Intermittent to Continuous Therapy for Diabetic Macular Edema leads to Reduction in Treatment Frequency and Reduced Retinal Thickness Fluctuations
Seenu M. Hariprasad, MD
On Demand Cases, Courses, and Papers
2019

Category: Diabetic Retinopathy

See more